Brain tumor
Glioblastoma multiforme (GBM) is the most aggressive (grade IV) and most common form of a malignant brain tumor. Even when aggressive multimodality therapy consisting of radiotherapy, chemotherapy, and surgical excision is used, median survival is only 12–17 months. Standard therapy for glioblastoma multiforme consists of maximal surgical resection of the tumor, followed by radiotherapy between two and four weeks after the surgical procedure to remove the cancer, then by chemotherapy, such as temozolomide. Most patients with glioblastoma take a corticosteroid, typically dexamethasone, during their illness to relieve symptoms. Experimental treatments include targeted therapy, gamma knife radiosurgery, boron neutron capture therapy and gene therapy.
Michael C. Ostrowski
Changes in BAI1 and Nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. 2014
Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1.
Cancer Res 74 738-50. 2014
The multifunctional protein fused in sarcoma (FUS) is a coactivator of microphthalmia-associated transcription factor (MITF).
J Biol Chem 289 326-34. 2014
MicroRNA 17-92 Cluster Mediates ETS1 and ETS2-Dependent RAS-Oncogenic Transformation.
PLoS One 9 e100693. 2014.
Protein kinase C Beta in the tumor microenvironment promotes mammary tumorigenesis.
Front Oncol 4 87. 2014